ORIGINAL RESEARCH
Published on 23 Aug 2022
Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
doi 10.3389/fonc.2022.920047
- 2,420 views
- 8 citations
- Frontiers in Oncology
- Thoracic Oncology
- Research Topics
- How to Select Patients with Thoracic Cancers for Immunotherapy-Chemotherapy or Immunotherapy-Angiogenesis Inhibitor Combinations?
How to Select Patients with Thoracic Cancers for Immunotherapy-Chemotherapy or Immunotherapy-Angiogenesis Inhibitor Combinations?
32k
Total Downloads
111k
Total Views and Downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
SYSTEMATIC REVIEW
Published on 10 Aug 2022
Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies
doi 10.3389/fphar.2022.920165
- 2,946 views
- 6 citations
ORIGINAL RESEARCH
Published on 20 Jun 2022
Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
doi 10.3389/fonc.2022.917089
- 1,409 views
- 5 citations
ORIGINAL RESEARCH
Published on 11 May 2022
A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
doi 10.3389/fonc.2022.713476
- 3,077 views
- 10 citations
ORIGINAL RESEARCH
Published on 16 Dec 2021
A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC
doi 10.3389/fonc.2021.722106
- 1,049 views
- 4 citations
ORIGINAL RESEARCH
Published on 13 Dec 2021
PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China
doi 10.3389/fonc.2021.745493
- 2,095 views
- 3 citations
ORIGINAL RESEARCH
Published on 12 Aug 2021
Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
doi 10.3389/fonc.2021.685047
- 1,923 views
- 7 citations
ORIGINAL RESEARCH
Published on 28 Jun 2021
Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
doi 10.3389/fonc.2021.691519
- 5,278 views
- 8 citations
SYSTEMATIC REVIEW
Published on 25 Jun 2021
The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small Cell Lung Cancer: A Meta-Analysis
doi 10.3389/fonc.2021.702924
- 2,299 views
- 6 citations
ORIGINAL RESEARCH
Published on 24 Jun 2021
Clinical Relevance of PD-L1 Expression and CD8+ T Cells’ Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma
doi 10.3389/fonc.2021.683432
- 2,362 views
- 14 citations
ORIGINAL RESEARCH
Published on 23 Jun 2021
First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
doi 10.3389/fonc.2021.657545
- 23,202 views
- 8 citations
CASE REPORT
Published on 21 Jun 2021
Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
doi 10.3389/fonc.2021.703318
- 1,660 views
- 3 citations
Published in
Frontiers in Oncology
- Thoracic Oncology
- Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore
Impact
- 111kTopic views
- 78kArticle views
- 32kArticle downloads